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Abstract
Aims Renal dysfunction (RD) is associated with increased morbidity and mortality in heart failure (HF). At present, no speciﬁc
treatment for patients with RD, to prevent progression of HF, has been developed. How different hormone axes—and thereby
potential treatment options—are affected by RD in HF warrants further investigations.
Methods and results Patients with left ventricular ejection fraction (LVEF) <0.45% were enrolled prospectively from an
outpatient HF clinic. Glomerular ﬁltration rate was estimated by the Chronic Kidney Disease Epidemiology Collaboration
equation (eGFR), and patients were grouped by eGFR: eGFR group I, ≥90 mL/min/1.73 m2; eGFR group II,
60–89 mL/min/1.73 m2; and eGFR group III, ≤59 mL/min/1.73 m2. Multivariate linear regression models were
developed to evaluate the associations between eGFR groups and hormones. A total of 149 patients participated in
the study. Median age was 69 [interquartile range (IQR): 64–73] and 26% were female; LVEF was 33% (IQR: 27–39),
78% were in functional class II–III, median eGFR was 74 (54–89) mL/min/1.73 m2, and median N-terminal pro-brain
natriuretic peptide was 1303 pg/mL (IQR: 441–2740). RD was associated with increased aldosterone, parathyroid
hormone (PTH), and copeptin concentrations (P < 0.05 for all) after adjustment for traditional confounders and
medical treatment.
Conclusions RD is associated with increased concentrations of aldosterone, PTH, and copeptin in systolic HF outpatients. Our
results underscore the importance of treatment with mineralocorticoid receptor antagonist in systolic HF in particular in
patients with RD and suggest that vasopressin and parathyroid receptor antagonism are potential treatment options in HF
patients with known RD.
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Introduction
Treatment with angiotensin converting enzyme
inhibitors/angiotensin II receptor blockers (ACE-I/ARB), beta-
blockers, mineralocorticoid receptor antagonists (MRAs), and
devices have improved outcome in systolic heart failure (HF).1
But treatment of the high-risk subgroup of patients with renal
dysfunction (RD) remains a challenge in daily clinical practice.2
RD is a frequent comorbidity in HF and associated with an
increased risk of re-admission, sudden cardiac death, and all-
cause mortality, but so far, no speciﬁc treatment for patients
with RD has been developed.3,4 Whether RD in outpatients with
systolic HF is associated with differential or increased activation
of different hormonal axes, which are traditionally evaluated in
patients with primary renal disease, has not been described
previously. This could be of interest, as these hormone axes
represent treatment targets in other populations of patients
with RD and might be targets in HF patients as well.5,6
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This prospective study tested the hypothesis that RD in
outpatients with systolic HF is associated with an increased
activity in hormones and prohormones reﬂecting
aldosterone status, calcium metabolism, and vasopressin
activity.
Methods
Patient population
Patients for the study were enrolled prospectively at their
ﬁrst visit to the HF clinic at Northzealand Hospital,
Denmark. Data was collected from January 2011 to
November 2012. All patients were known to have systolic
HF and left ventricular ejection fraction (LVEF) <45% and
were referred to the clinic for uptitration of guideline-
recommended therapy.7,8 For enrolment in the study, it was
required that plasma creatinine had been stable (±10 μmol/L)
for a period of 60 days and the patient is in stable condition,
deﬁned as out of hospital for a minimum of 60 days. The
only exclusion criterion was inability to provide informed
consent.
At an additional visit to the HF clinic, the following were
obtained: New York Heart Association (NYHA) classiﬁcation,
medical history, current medication, symptoms, weight,
height, and electrocardiogram. Description of coronary
angiography was retrieved when available, for categorizing
the patients as having non-ischemic or ischemic heart disease
(IHD).9 Patients collected a 24 h urine sample, starting on the
day before the exam. Fasting venous blood samples were
drawn, and patients underwent echocardiography. Additional
samples for aldosterone and renin were drawn after 30 min
of supine rest. The study complies with the Declaration of
Helsinki and approved by the local ethics committee (H-1-
2010-074); all patients provided informed, written, and oral
consent.
Renal function
Renal function was estimated by the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation incorporating
age, race if Black, gender, and plasma creatinine
concentration, which has been validated in HF and found to
be more accurate than other creatinine-based equations.10–
12 Patients were divided into groups according to estimated
glomerular ﬁltration rate (eGFR): eGFR group I,
≥90 mL/min/1.73 m2; eGFR group II, 60–89 mL/min/
1.73 m2; and eGFR group III, ≤59 mL/min/1.73 m2. Intervals
for eGFR groups were chosen, so they matched CKD stages
as speciﬁed by the National Kidney Foundation Kidney
Disease Outcomes Quality Initiative Guidelines.13
Biochemical analyses
After >8 h overnight fast, venous blood samples were
obtained and directly analysed for haemoglobin, creatinine,
sodium, and potassium. Additional samples for measurement
of plasma aldosterone and renin were taken after 30 min rest
in the supine position. Albuminuria was deﬁned by an
albumin excretion rate ≥ 30 mg/24 h. For later analysis,
plasma was collected in ethylenediamine tetracetic acid vials
and centrifuged at 4°C (3000 rpm in 10 min), and the plasma
was stored at 80°C in aliquots. N-terminal pro-brain
natriuretic peptide (NT-proBNP; 1–76) concentration was
measured on the Dimension Vista® 1500 from Siemens
Medical Solutions Diagnostics using the LOCI® technology
(luminescent oxygen channelling assay) (Malvern, PA, USA)
according to the manufacturers’ procedures.14 Plasma
concentrations of copeptin were measured on the Kryptor
Compact platform (BRAHMS, Hennigsdorf, Germany). Assay
validation has been reported previously.15
Statistical analyses
Baseline clinical and biochemical data are reported as mean
for normally distributed variables and medians for skewed
distributions and presented with ﬁrst and third quartiles
(Q1–Q3). Basic clinical variables between eGFR groups were
compared by χ2 tests for discrete variables and one-way
ANOVA tests (parametric) and Kruskal–Wallis tests (non-
parametric) for continuous variables, as appropriate.
Hormones, pro-hormone, and vitamin D were transformed
by the log10 algorithm and tested with simple general linear
models in Table 1. As some previous studies of aldosterone in
HF have used a deﬁnition of excess aldosterone, when plasma
aldosterone was >400 pmol/L (>144 pg/mL) and urinary
aldosterone excretion was >33.3 nmol/24 h (>12 μg/24 h),
the occurrence of abnormal aldosterone concentrations was
also evaluated according to this deﬁnition and is presented
in Table 1.16,17
For further analyses, the association between the log-
transformed hormones/pro-hormone and concentrations of
urinary cations (Mg2+ and K+) and eGFR groups were
evaluated in multivariate linear models. The multivariate
models were all adjusted for the following explanatory
variables: eGFR, age, gender, diabetes, LVEF, atrial ﬁbrillation
(AF), hypertension, IHD, ACE-I/ARB, and MRA treatment. To
each model, biological relevant explanatory variables were
added, as follows: model for parathyroid hormone (PTH) as
response variable, P-calcium and 25-OH-vitamin D; model
for aldosterone as response variable, renin and potassium;
and model for copeptin as response variable, P-sodium and
systolic blood pressure.
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We further tested the association between the HF
markers, LVEF, NT-proBNP, NYHA class, and the
hormones, in univariate and multivariate analyses with
and without eGFR in the models; these results are
presented in Table S1 a–c.
To avoid overlooking a moderate effect of eGFR on
hormone levels (β: 0.80), at a signiﬁcance level of 0.05 (α) in
a multivariate regression model including eight covariates, n
was calculated at 108.18 A total of n = 150 patients were
recruited to account for possible missing data. For all
analyses, a two-sided P-value of <0.05 was considered
signiﬁcant.
Results
Patient characteristics
A total of 230 patients were referred to the clinic: 61 declined
to participate, 20 accepted but did not show for the
Table 1 Patient characteristics
Variable All eGFR group I eGFR group II eGFR group III P-value
n 149 46 66 47
Age years 69 (64–73) 61 (56–66) 71 (67–75) 73 (70–79) <0.001
Sex. female % 26 31 21 28 0.538
BMI kg/m2 27 (24–30) 27 (24–31) 27 (24–30) 27 (23–30) 0.937
Heart rate 70 (60–80) 71 (60–81) 68 (58–79) 70 (60–82) 0.534
Systolic BP mmHg 125 (112–140) 130 (117–152) 124 (114–136) 120 (108–139) 0.121
Diastolic BP mmHg 77 (69–85) 80 (72–84) 77 (69–84) 71 (65–79) 0.016
LVEF % 33 (27–39) 33 (28–40) 34 (27–40) 31 (25–38) 0.566
NYHA 0.017
I % 20 22 23 15 .
II % 52 72 49 43 .
III % 26 6 27 38 .
IV % 2 0 2 4 .
AF % 38 36 39 36 0.921
Hypertension % 62 64 65 57 0.632
DM % 21 17 20 28 0.431
IHD % 58 45 55 70 0.095
Anaemia % 29 14 26 43 0.011
Beta-blockers % 87 90 88 83 0.657
ACE-I/ARB % 95 97 96 91 0.335
MRA % 21 11 21 28 0.202
Diuretics % 72 64 73 79 0.324
Vitamin D suppl % 12 11 6 23 0.025
Sodium (mmol/L) 138 (136–140) 138 (135–140) 138 (136–140) 138 (136–141) 0.533
Potassium (mmol/L) 4.3 (4.1–4.7) 4.2 (3.9–4.5) 4.3 (4.1–4.6) 4.4 (4.1–4.7) 0.104
Creatinine (μmol/L) 86 (71–108) 65 (53–74) 81 (795) 127 (110–160) <0.001
Phosphate (mmol/L) 1.18 (0.99–1.26) 1.13 (0.98–1.25) 1.09 (0.98–1.16) 1.23 (1.06–1.39) 0.002
Ion-calcium (mmol/L) 1.21 (1.18–1.23) 1.22 (1.19–1.24) 1.21 (1.18–1.23) 1.20 (1.17–1.24) 0.299
Hgb (mmol/L) 8.5 (7.9–9.2) 8.8 (8.4–9.4) 8.6 (7.9–9.3) 8.2 (7.4–8.8) 0.018
eGFR (mL/min/1.73 m2) 74 (54–89) 96 (93–101) 78 (70–86) 46 (36–54) <0.001
Urine All eGFR group I eGFR group II eGFR group III P-value
U-Magnesium excret. mmol/24 h 4.0 (3.0–5.0) 4.1 (3.0–5.0) 4.1 (3.0–5.0) 3.7 (2.0–5.0) 0.588
U-Potassium excret. mmol/24 h 74.6 (57.0–90.5) 74.5 (54.0–91.0) 77.8 (61.0–91.0) 69.9 (50.0–88.0) 0.448
U-aldosterone excess % 22 26 23 17 0.707
Albuminuriaa % 20 20 13 28 0.202
Hormones All eGFR group eGFR group eGFR group P-value
Aldosterone excessa % 17.3 8.8 14.3 28.6 0.053
P-Aldosterone (pmol/L) 154 (91–309) 138 (86–266) 144 (80–252) 194 (102–484) 0.033
P-PTH (pmol/L) 7.6 (5.0–11.8) 5.7 (4.1–8.9) 7.2 (5.5–11.2) 10.1 (6.4–17.2) 0.001
P-25-OH-vitamin D (nmol/L) 66.8 (47.7–89.5) 59 (40.1–74.4) 62 (40.3–74.3) 69 (47.8–89.5) 0.334
P-Cortisol (nmol/L) 430 (358–524) 397 (304–482) 433 (363–524) 449 (383–544) 0.122
P-Renin ×103 i.u. 4.2 (1.05–12.62) 4.0 (0.6–10.8) 4.5 (1.0–12.8) 4.4 (1.5–28.0) 0.302
P-NT-proBNP (pg/mL) 1303 (441–2740) 527 (325–1201) 1132 (400–2240) 3129 (1514–5367) <0.001
P-Copeptin (pmol/L) 9.31 (5.9–17.7) 6.2 (4.6–8.2) 9.0 (5.9–14.5) 21.3 (9.9–43.2) <0.001
AF, atrial ﬁbrillation; ACE-I/ARB, angiotensin converting enzyme inhibitors/angiotensin receptor blockers; BMI, body mass index; BP, blood
pressure; DM, diabetes mellitus; eGFR, estimated glomerular ﬁltration rate; excret, excretion; Hgb, haemoglobin; IHD, ischemic heart
disease; LVEF, left ventricle ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-brain natriuretic
peptide; NYHA, New York Heart Association functional class.
Data are presented as mean or median with interquartile ranges. P-values for the 0-hypothesis: no difference between groups I–III at a
0.05 signiﬁcance level (please see section Methods, statistical analyses).
aAlbuminuria was deﬁned by albumin excretion rate ≥ 30 mg/24 h.
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additional visit, and ﬁnally, 149 patients participated in the
study. Patient characteristics for the entire cohort and
stratiﬁed according to eGFR group are listed in Table 1.
Median age was 69, and 26% were female; median LVEF
was 33%, and 38% had AF at the time of the exam; 58%
had IHD deﬁned by coronary angiography descriptions.9
Patients with lower renal function/lower eGFR, that is, eGFR
group III, were older and had lower levels of haemoglobin
and higher concentrations of aldosterone, PTH, and copeptin
in the univariate models; but occurrence of excess
aldosterone did not differ signiﬁcantly (P = 0.053). There
were no signiﬁcant differences in frequencies of AF,
hypertension, body mass index, diabetes, IHD, or medication.
Notably there was no difference in concentrations of P-ion-
calcium, P-25-OH-vitamin D, or P-cortisol.
Owing to discrepancy in occurrence of excess plasma
concentration of aldosterone and elevated urinary
aldosterone according to eGFR groups, the association
between the two variables was evaluated in a univariate
linear regression model with log10(urinary aldosterone
excretion) as response variable and log10(p-aldosterone) as
explanatory variable, and they were found to be signiﬁcantly
associated (P < 0.001). When eGFR was added as
explanatory variable to the model, the association between
urinary excretion and plasma concentrations of aldosterone
remained signiﬁcant (P < 0.001). There was no association
between log10(urinary aldosterone excretion) and eGFR in a
univariate linear model (P = 0.903).
Multivariate linear regression models
In the multivariate linear regression models, aldosterone,
copeptin, and PTH concentrations were associated with eGFR
group after adjustment for the predeﬁned confounders. There
were no signiﬁcant differences in urinary cations or urinary
aldosterone. Beta coefﬁcients for eGFR in the multivariate
models for each hormone are presented in Table 2.
P-values for the multivariate models for log-transformed
hormones/pro-hormone according to eGFR group are
presented as bar plots in Figure 1a–c.
We constructed a multivariate logistic regression model for
excess aldosterone as a binary variable adjusted for the same
explanatory variables as described for the linear models and
found a signiﬁcant association with eGFR groups (P = 0.026)
(data not presented in tables).
More patients in the eGFR groups with a low eGFR
reported taking an MRA. Despite that the intake did not differ
signiﬁcantly between the groups (P = 0.202; Table 1), it might
have resulted in a secondary increase in aldosterone
concentrations contributing to the observed association
between eGFR and plasma aldosterone; so we repeated the
multivariate linear model with log10(aldosterone) as response
variable with and without MRA as a covariate, and the
association with eGFR group remained signiﬁcant (without,
P = 0.021; with, P < 0.001).
Univariate and multivariate analyses of the
hormones and LVEF, NYHA class, and NT-proBNP
Aldosterone was not associated with LVEF (P = 0.404) or NT-
proBNP (P = 0.126) in univariate analyses, but only when
entering eGFR and/or the predeﬁned covariates in
multivariate analyses. Aldosterone was associated with NYHA
class (P = 0.012) in both univariate and multivariate analyses,
with and without eGFR.
PTH was not associated with LVEF (P = 0.586) in univariate
analyses but was associated with NYHA class (P = 0.008) and
NT-proBNP (P = 0.004) in univariate models. eGFR was
associated with the hormone in all the models.
Copeptin was not associated with LVEF (P = 0.127) in
univariate analyses but became signiﬁcant when adjusted
for the covariates (P = 0.032) and was associated with eGFR
in all the models (P < 0.05). Copeptin was associated with
NYHA class and NT-proBNP in all models (all P < 0.05).
Please refer to Table S1 a–c for all results.
Discussion
In this cross-sectional study investigating systolic HF patients
with and without RD, we observed that RD was associated
with increased plasma concentrations of aldosterone, PTH,
Table 2 The relationship between hormones/pro-hormone and renal function in multivariate linear regression models
Model for β coefﬁcient for eGFR 95% CI P-value
Log10(aldosterone) 0.0038 (0.006 to 0.001) 0.018
Log10(parathyroid hormone) 0.0049 (0.004 to 0.003) <0.001
Log10(copeptin) 0.0118 (0.014 to 1.009) <0.001
CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate.
All models were adjusted for age, sex, body mass index, left ventricle ejection fraction, atrial ﬁbrillation, history of hypertension and use of
mineral corticoid receptor antagonists, and angiotensin converting enzyme inhibitors/angiotensin receptor blockers. Furthermore, the
models were adjusted as follows; parathyroid hormone, P-calcium and P-25-OH-vitamin D; aldosterone, P-renin and P-potassium; and
copeptin, P-sodium and systolic blood pressure.
Effect of renal impairment on hormones in chronic heart failure 557
ESC Heart Failure 2017; 4: 554–562
DOI: 10.1002/ehf2.12186
and copeptin. These hormone axes represent potential
treatment targets in the chronic cardiorenal syndrome,
and our analyses underscore the importance of treatment
with aldosterone antagonism in HF, in particular in patients
with RD.
Aldosterone status
We observed a signiﬁcant association between RD and
aldosterone in the multivariate analyses (Figure 1a). The
increased aldosterone concentrations observed in HF
patients with RD are a plausible contributing factor to the
increased mortality and morbidity associated with RD in
HF.1,4 Blocking of the mineralocorticoid receptor with the
MRAs spironolactone and eplerenone has been a large
progress in reducing mortality and morbidity in HF.19,20 In
addition, spironolactone was found to have greater absolute
effect on mortality in the subgroup of HF patients with an
eGFR < 60 mL/min/1.73 m2, which supports our ﬁnding in
the multivariate analyses.20
Reduced GFR is mainly due to decreased renal blood ﬂow in
HF patients, which also activates the renin–angiotensin–
aldosterone system (RAAS) and the sympathetic nervous
systems. Thus, reduced renal blood ﬂow is a possible trigger
of the increased aldosterone in the present study.21,22
However, P-renin and P-cortisol were not increased in patients
with RD, and the precise mechanism for the observed
increased aldosterone concentration cannot be deduced from
our data. Urinary excretion of aldosterone did not increase
with decreasing eGFR (Table 1). However, as observed in the
ALOFT study, we found a signiﬁcant association between
plasma aldosterone concentrations and urinary excretion of
aldosterone.17 A possible explanation for the discrepancy
between plasma aldosterone and urinary excretion of
aldosterone according to eGFR group could be a decrease in
renal clearance of aldosterone with declining eGFR.
The ﬁnding of increased aldosterone concentrations in HF
patients with RD underscores the importance of development
for new treatment strategies for blocking of aldosterone-
induced effects, as the guideline-recommended MRAs are
under-utilized in this group, owing to risk of hyperkalaemia
and decrease in renal function.7,8,23 In the ARTS-HF trial, a
non-steroidal MRA, ﬁnerenone, is being investigated as an
alternative to spironolactone and eplerenone in HF patients
with reduced eGFR.24,25 The results are promising, as the
Phase IIb trial showed a similar safety proﬁle as eplerenone
but less frequent occurrence of hyperkalaemia and lower
events rates of the secondary endpoint of death,
hospitalization of worsening of HF in patients with moderate
kidney disease with an eGFR of 30 to <59 mL/min/1.73 m2.26
Calcium metabolism
We observed that RD was associated with increased PTH
concentrations. Increased plasma concentrations of PTH in
Figure 1 (A–C) Concentrations of hormones according to estimated
glomerular ﬁltration rate (eGFR) group. Data bars represent the median
level and third quartile of hormones. P-values for linear regression
models adjusted for age, sex, body mass index, left ventricular ejection
fraction, atrial ﬁbrillation, history of hypertension, and use of
mineralocorticoid receptor antagonists and angiotensin converting
enzyme inhibitors/angiotensin receptor blockers. Furthermore, the
models were adjusted for parathyroid hormone (PTH), P-calcium and P-
25-OH-vitamin D; aldosterone, P-renin and P-potassium; and copeptin,
P-sodium and systolic blood pressure.
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HF have been described previously and were in these studies
related to HF severity, re-admission rates, and mortality risk;
but an association between RD and PTH concentrations in HF
has not been reported previously.27–29
The exact trigger for increased PTH in HF is unknown.30 A
suggested explanation is activation of RAAS with
aldosterone-stimulated faecal and urinary excretion of
cations and intracellular storing of Ca2+, resulting in low
concentrations of extracellular Ca2+ and secondary
hyperparathyroidism to restore extracellular Ca2+.30,31 As
described for aldosterone, reduced renal blood ﬂow in RD is
a possible trigger for increased activation of this pathway.
However, we did not observe an increased urinary excretion
of magnesium or potassium in patients with RD supportive
of this explanation (Table 1).
Another possible trigger for the increased concentrations
of PTH could be initial hypocalcaemia due to vitamin D
deﬁciency, but we did not observe any difference in P-25-
OH-vitamin D concentrations in the present study. This may
be due to a difference in 25-OH-vitamin D supplementation
(Table 1). Furthermore, unmeasured active vitamin D (1,25-
OH-vitamin D) produced by the kidneys may be decreased
in patients with RD despite normal plasma concentrations
of inactive 25-OH-vitamin D, and the normalization of plasma
concentrations of Ca2+ may be the net result of deﬁciency of
active 1,25-OH-vitamin D and increased concentrations of
PTH. Whether treatment with paricalcitol (active 1,25-OH
vitamin D) or cinacalcet (PTH receptor antagonist) can
improve outcome in systolic HF patients with RD and
secondary hyperparathyroidism remains to be determined,
but an effect on secondary cardiovascular endpoints in
patients with chronic kidney disease has been observed in
two randomized clinical trials.5,6 However, treatment with
inactive 25-OH-vitamin D has no effect on quality of life or
functional class in systolic HF patients.32
Vasopressin activity
We observed that copeptin concentrations were increased in
patients with RD, in accordance with previous studies.33 The
association with RD may be due to arterial underﬁlling and
baroreﬂex activation.34 Increased copeptin concentrations
have been shown to predict mortality risk and risk of re-
admission in HF.33,35
In the EVEREST trial, treatment with a vaptan failed to
improve long-term clinical outcome in HF.36 However, this
result may reﬂect selection of patients in whom the
vasopressin system was not particularly activated, because
neither elevated copeptin nor vasopressin nor
hyponatraemia was an inclusion criterion. In theory, systolic
HF patients with RD and increased copeptin concentrations
may beneﬁt from treatment with a vaptan, but this requires
further investigation.
Relationship between cardiac function and the
hormones
The additional analyses on the relationship between LVEF,
NYHA, and NT-proBNP and the three hormones did not show
a speciﬁc association with LVEF but did show a speciﬁc
association to some degree with NYHA class and NT-proBNP,
which again could be argued to reﬂect the degree of both HF
and renal function.
There was only a signiﬁcant association when eGFR and
the clinical covariates were entered in the models, suggesting
that the increased levels of the hormones are related to the
presence of RD and not to HF alone. As increased levels of
these hormones have been shown to be associated with
mortality in HF populations,27,28,33,37 our results suggest that
targeting the hormone axes in future trials possibly should be
limited to HF patients with known moderate RD or increased
levels of the hormones.
Limitations
Some methodological strengths and limitations should be
discussed. The generalizability of our data is limited to
patients with systolic HF, considered eligible for uptitration
in neurohormonal blockade and therefore represent a
selected population. The results should not be extrapolated
to patients with acute, advanced, or terminal HF. The
included patients were examined during their ﬁrst phase of
uptitration of HF medication, with no speciﬁc criteria
regarding status of medication. One could argue that the
patients should have been examined either before any
medication or after full uptitration to be strictly comparable.
As the medication for treating HF is also used for
hypertension and post-myocardial infarction, it is, however,
difﬁcult to investigate a HF population not being treated at
all. Furthermore, HF is a chronic condition frequently without
an index event like in cohorts with a myocardial infarction,
which also complicate to determine the optimal experimental
day from a strict point of view. Waiting to end uptitration
would likely cause some selection bias (results would have
been biased towards zero), as some patients especially
patients with a low eGFR would have died, but selection bias
in the other direction could also be the case in that patients
with a low eGFR do not tolerate target doses of medication.
Investigation in relation to the baseline visit in the outpatient
HF clinic was therefore chosen.
The present three eGFR groups were used owing to the
sample size, and it may have resulted in eGFR group I
containing both patients with no renal disease, impairment
due to age, or mild renal disease. As it has been shown, eGFR
is a strong prognostic factor in HF and the three groups are,
therefore, considered clinical meaningful. Albuminuria is also
a prognostic factor in HF, and more knowledge on this
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variable is needed. We did not differ between
microalbuminuria or macroalbuminuria, and the aetiology of
proteinuria cannot be deduced from our results.38
When interpreting our results, it has to be remembered
that chronic kidney disease is an inhomogeneous disease,
and for example, reduced renal blood ﬂow and parenchymal
renal disease may affect hormones differently. We may have
underestimated the effect of RD on the different hormone
axes owing to misclassiﬁcation (=bias towards zero) of GFR
induced by the CKD-EPI formula,11 and it may explain why
RD and aldosterone excess were only associated signiﬁcantly
in the multivariate analyses. As mentioned in the discussion,
increased copeptin levels may represent increased
vasopressin production owing to arterial underﬁlling and
renal vasoconstriction and also simply decreased clearance
due to RD. Unmeasured confounding due to lack of
measurement of 1,25-OH-vitamin D may in theory partly
explain the association between RD and increased PTH
concentrations as previously discussed, but it does not
change the conclusion that calcium metabolism is affected
in systolic HF patients with RD. Thus, the observed statistical
associations are all biological plausible and are observed in
cohorts of patients with chronic kidney disease without
systolic HF, making our results likely. No measurements of
activation of phosphate homeostasis through activation of
FGF23–Klotho axis were performed, and whether some of
the patients had secondary hyperparathyroidism due to
increased FGF23 cannot be determined.
The strengths of the present data are a precise clinical and
biochemical characterization of 149 systolic HF patients
recruited from daily clinical practice, and we succeeded in
collecting 24 h urine samples in this elderly population. Based
on our results, Phase II and III trials evaluating antagonism of
vasopressin and PTH are intriguing perspectives to improve
outcome in the chronic cardiorenal syndrome. A third
possibility could be further evaluation of a treatment strategy
with non-steroidal MRA as second option, when withdrawal
of the traditional steroidal MRAs is necessary owing to rising
potassium or reduced renal function, as was carried out in
the CHARM alternative trial.39
Conclusions
RD is associated with increased concentrations of
aldosterone, PTH, and copeptin in systolic HF outpatients.
Our results underscore the importance of treatment with
MRA in systolic HF, in particular in patients with RD, and
suggest that vasopressin and parathyroid receptor
antagonism are potential treatment options in HF patients
with known RD.
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